Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer

Alegría-Baños, Jorge A.; Jiménez-López, José C.; Vergara-Castañeda, Arely; de León, David F. C.; Mohar-Betancourt, Alejandro; Pérez-Montiel, Delia; Sánchez-Domínguez, Gisela; García-Villarejo, Mariana; Olivares-Pérez, César; Hernández-Constantino, Ángel; González-Santiago, Acitlalin; Clara-Altamirano, Miguel; Arela-Quispe, Liz; Prada-Ortega, Diddier

Ovarian cancer (OC) is considered the most lethal gynecological cancer, of which more than 65% cases are diagnosed in advanced stages, requiring platinum-based neoadjuvant chemotherapy (NACT).

A prospective-longitudinal study was conducted among women with advanced epithelial ovarian cancer (AEOC), III and IV stages, and treated with NACT, at the National Cancer Institute – Mexico, from July 2017 to July 2018. Serum samples were obtained for quantification of CA125 and HE4 using ELISA at the first and in each of the three NACT cycles. The therapeutic response was evaluated through standard tomography. We determined whether CA125 and HE4, alone or in combination, were associated with TR to NACT during follow up.

53 patients aged 38 to 79 years were included, 92.4% presented papillary serous subtype OC. Higher serum HE4 levels were observed in patients with non-tomographic response (6.89 vs 5.19 pmol/mL; p = 0.031), specially during the second (p = 0.039) and third cycle of NACT (p = 0.031). Multivariate-adjusted models showed an association between HE4 levels and TR, from the second treatment cycle (p = 0.042) to the third cycle (p = 0.033). Changes from baseline HE4 levels during the first cycle was negative associated with TR. No associations were found between CA125 and TR.

Serum HE4 levels were independently associated with TR among patients with AOEC treated with NACT, also a reduction between baseline HE4 and first chemotherapy levels was also independently associated with the TR. These findings might be relevant for predicting a lack of response to treatment.

Geographic Areas


  • thumnail for 13048_2021_Article_845.pdf 13048_2021_Article_845.pdf application/pdf 275 KB Download File

Also Published In

Journal of Ovarian Research

More About This Work

Published Here
September 22, 2023


Biomarkers kinetic, HE4, CA125, Gynecological cancer, Ovarian cancer, Neoadjuvant chemotherapy